Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience
Part of paid clinical trials in Overland Park, Kansas.
- Sponsor
- Viatris Inc.
- Study ID
- NCT07777965
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Healthy Non-dependent, Recreational Sedative Users
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Alprazolam (Xanax) — DRUG2mg
- Placebo — DRUGplacebo
- Gabapentin (Neurontin® (Registered Trademark)) — DRUG1200mg
- Gabapentin (Neurontin® (Registered Trademark)) — DRUG1800mg
Study Details
The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent recreational sedative drug users under fasted condition.
Key Dates
- First listed
- Aug 21, 2026
- Start date
- Jun 18, 2026
- Status verified
- Aug 2026
- Primary completion
- Nov 30, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- OTHER
Arms
- Active Comparator: Treatment Phase A
- Placebo Comparator: Treatment Phase B
- Active Comparator: Treatment Phase C
- Active Comparator: Treatment Phase D
Primary Outcome Measure
Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax) [ Time Frame: Up to 24 hours after treatments ]
Central Contacts
- Dik Ng(+44) 1304626895
- Laura Zachwieja(+1) 304 5992595
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dr. Vince Clinical Research | Overland Park | Kansas | 66212 | - |
Find similar trials in Overland Park, KS
By research site